Back to School: How biopharma can reboot drug development. Access exclusive analysis here
BioAtla's VivaMab therapeutic development division granted ADC Therapeutics rights to VivaMab's VM101 for hematologic
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury